MedTrace Logo

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

NCT01841359 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-06-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether pramlintide (Symlin) will help to reduce the frequency and severity of hypoglycemia in individuals who have had gastric bypass surgery.

Conditions

Interventions

DRUG

Pramlintide

See description above (arm description).

Sponsors & Collaborators

Principal Investigators

  • Mary E. Patti, MD · Joslin Diabetes Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-02
Primary Completion
2016-07-31
Completion
2022-02-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01841359 on ClinicalTrials.gov